Published in final edited form as:

Obes Surg. 2015 February ; 25(2): 381–385. doi:10.1007/s11695-014-1485-6.

Effects of Roux-en-Y gastric bypass surgery on visceral and subcutaneous fat density by computed tomography

Martin Torriani, M.D., M.Sc.¹, Adriana L. Oliveira, M.D.¹, Debora C. Azevedo, M.D.¹, Miriam A. Bredella, M.D.¹, and Elaine W. Yu, M.D., M.Sc.²

¹Division of Musculoskeletal Imaging and Intervention, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, USA

²Department of Medicine, Endocrine Unit; Massachusetts General Hospital and Harvard Medical School, Boston, USA

Abstract

We aimed to test the hypothesis that noninvasive fat density by computed tomography (CT) increases after Roux-en-Y gastric bypass (RYGB) and correlates with improved cardiometabolic risk. We examined 21 obese adults before and 12 months after RYGB and 16 obese nonsurgical controls followed for 12 months. Visceral (VAT) and subcutaneous adipose tissue (SAT) density increased after RYGB ($P<0.0001$) while remaining stable in controls ($P=0.1$). In RYGB subjects, 12-month increase in VAT density correlated with decreased CRP independent of change in VAT area or BMI (both $P<0.05$). Twelve-month increase in SAT density correlated with increased HDL-cholesterol independent of change in SAT area ($P=0.048$), BMI ($P=0.03$), or statin use ($P=0.002$), and 1 unit increase in SAT density had increased odds of higher total abdominal fat loss ($P=0.002$).

INTRODUCTION

Expansion of visceral adipose tissue (VAT) strongly correlates with increased cardiometabolic risk, while accumulation of abdominal subcutaneous adipose tissue (SAT) has more modest associations with inflammatory biomarkers [1]. Although VAT and SAT volumes are frequently measured by computed tomography (CT), fat density measures may also provide information about clinical risk [1]. CT imaging can assess fat characteristics because pixel values are measured in a scale that informs tissue radiodensity. Within the fat range [–250 to –50 Hounsfield units (HU)], lower density is associated with more lipidic

Corresponding to: Martin Torriani, M.D., M.Sc., Division of Musculoskeletal Imaging and Intervention, Department of Radiology, Massachusetts General Hospital, 55 Fruit Street – YAW 6048 – Boston, MA – 02114, Phone: 617-724-1108 – Fax: 617-726-5282, mtorriani@mgh.harvard.edu.

CONFLICT OF INTEREST DISCLOSURE STATEMENT

The authors declare that they have no conflict of interest.

STATEMENT OF INFORMED CONSENT

Informed consent was obtained from all individual participants included in the study.

STATEMENT OF HUMAN AND ANIMAL RIGHTS

Studies have been approved by the appropriate institutional and/or national research ethics committee and have been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

content while higher density reflects increased vascularity [2]. A prior population-based cross-sectional study described associations between abdominal fat density and cardiometabolic risk markers independent of BMI and fat mass [1]. However, fat density in a severely obese population and after bariatric surgery is unknown. Bariatric surgery dramatically improves metabolic outcomes, the mechanisms of which may extend beyond weight loss and involve reductions in inflammatory adipokines secreted by VAT and SAT. This longitudinal study aimed to measure abdominal fat density by CT, before and 12 months after Roux-en-Y gastric bypass (RYGB), with the hypothesis that fat density increases after surgery and correlates with improved cardiometabolic risk markers.

MATERIALS AND METHODS

Study subjects and protocol

This study was approved by the Institutional Review Board of Partners HealthCare, Inc. and all subjects provided written informed consent. Recruitment criteria, clinical characteristics, bone mineral density, and biochemical markers of bone formation and resorption were previously described [3], however no data on VAT and SAT characteristics, C-reactive protein (CRP) and serum lipids have been published. Briefly, 30 subjects scheduled for RYGB and 20 nonsurgical obese controls (all >18 years) were recruited having similar age, sex, and weight. Exclusion criteria were weight >200kg (due to imaging equipment limitations), pregnancy, and history of hyperthyroidism or renal disease. Nine surgical subjects were excluded entirely (1 for not obtaining baseline abdominal CT images, 1 for unavailable CT images, 7 for excessive CT artifact). Four nonsurgical subjects were excluded entirely for excessive CT artifact. Two nonsurgical subjects dropped out and one surgical subject was converted to sleeve gastrectomy, thus were included only in baseline analyses. The study group at baseline comprised 37 subjects (surgical n=21, nonsurgical n=16). Use of 3-hydroxy-3-methyl-glutaryl-CoA-reductase inhibitors (statins) was recorded at both visits.

Fat depot measures and laboratory data

CT scans were performed using a 16-multidetector row scanner (LightSpeedPro, General Electric, Waukesha, WI, USA) with 2.5mm slice thickness, 120kVp, and 100mA. Abdominal circumference (cm), cross-sectional areas (cm²) and mean HU for VAT, SAT, and total abdominal adipose tissue (TAT) were measured at the level of L2–3 by experienced radiologists using semiautomated tracings with density thresholds between –250 and –50HU (Aquarius, TeraRecon Inc., San Mateo, CA). Fasting serum glucose, lipids (total, HDL- and LDL-cholesterol, triglycerides), and C-reactive protein (CRP) were collected after an overnight fast and measured by particle enhanced turbidimetric assay kits from Roche Diagnostics (Indianapolis, IN, USA) with range of 1.0–200 mg/L and coefficient of variation of 1.8%.

Statistical analyses

Statistical analyses were conducted by Wilcoxon Signed Rank test for within- and between-group comparisons. Associations were examined using Spearman's correlation. Standard least squares modeling controlled for BMI, VAT or SAT area was used to examine

correlations between VAT and SAT density with other parameters. We divided 12-month TAT change into high- and low-TAT loss based on TAT median value and logistic regression determined odds ratios (OR) per unit change in SAT density. Analyses were performed using JMP 11 (SAS, Cary, NC, USA). $P < 0.05$ was considered significant. Values are mean $\pm$ SD.

RESULTS

Fat density at baseline

Baseline characteristics of included subjects are outlined in Table 1. Subjects excluded for imaging artifacts had higher baseline weight, BMI and abdominal circumference and lower LDL-cholesterol compared to included subjects ($P < 0.05$), with remaining parameters being similar ($P > 0.05$).

Surgical and nonsurgical groups had similar baseline BMI, VAT and SAT densities and areas (all $P = 0.6$). In all subjects, VAT density correlated negatively with VAT area ($r = -0.56$, $P = 0.0003$; $P = 0.006$ after BMI adjustment). Similarly, SAT density correlated negatively with SAT area ($r = -0.46$, $P = 0.006$) however significance was lost after BMI adjustment ($P = 0.5$). Baseline VAT density correlated negatively with CRP independent of BMI ($r = -0.46$, $P = 0.006$) or VAT area ($r = -0.6$, $P = 0.003$). SAT density was not associated to CRP ($P = 0.2$).

Fat density increases after RYGB

Twelve months after RYGB, VAT and SAT density increased in the surgical group ($10 \pm 7\%$ and $12 \pm 7\%$ respectively, both $P < 0.0001$), and were significantly higher than nonsurgical subjects (both $P < 0.001$) (Table 1, Figures 1A and 1B). VAT and SAT area decreased in the surgical group ($-55 \pm 21\%$ and $-43 \pm 20\%$, both $P < 0.0001$), and were significantly lower than nonsurgical subjects at 12 months (both $P < 0.001$) (Figures 1C and 1D). Surgical subjects had within-group decreased CRP ($-59 \pm 64\%$, $P = 0.0003$), serum triglycerides ($-27 \pm 27\%$, $P = 0.0006$) and LDL-cholesterol ($-15 \pm 28\%$, $P = 0.02$), increased HDL-cholesterol ($40 \pm 35\%$, $P < 0.0001$), with fasting glucose ($P = 0.1$) and total cholesterol ($P = 0.2$) being unchanged. In nonsurgical subjects, within-group 12-month changes were not significant in all laboratory parameters ($P = 0.1$). Changes in fasting glucose ($P = 0.02$), triglycerides ($P = 0.01$) and HDL-cholesterol ($P = 0.005$) were significantly different between groups at 12-months (remaining $P > 0.1$).

Increases in fat density after RYGB correlate with improved metabolic indices

Within the surgical group, 12-month increase in VAT density correlated with decreased CRP independent of change in VAT area or BMI (both $r = -0.55$, $P < 0.05$). Twelve-month increase in SAT density correlated with increased HDL-cholesterol independent of change in SAT area ($r = 0.79$, $P = 0.048$), BMI ($r = 0.70$, $P = 0.03$), or statin use at 12 months ($r = 0.77$, $P = 0.002$). We found no association between increased VAT or SAT density with change in fasting glucose ($P > 0.7$). In subjects from the surgical group, an increase of 1 HU in SAT density at 12 months was associated with increased odds of high TAT loss [OR: 1.36 (95% CI: 1.1–1.9), $P = 0.002$].

DISCUSSION

Our study shows that lower VAT density correlates with higher CRP levels in morbidly obese adults, independent of BMI or VAT area. Furthermore, in the first year after RYGB, VAT and SAT densities increase concurrent with fat loss, correlating with improved metabolic indices independent of BMI and predicting higher total fat loss.

VAT and SAT density may be linked to adipose lipid content and vascularity. Lower CT density in adipose tissue suggests lipid-rich fat and adipocyte hypertrophy [1], and may reflect decreased vascularity of adipose tissue [2]. Importantly, adipocyte size is positively associated with insulin resistance, diabetes, and macrophage burden, and is negatively associated with adiponectin secretion. Moreover, dysfunctional and hypertrophied adipose tissue has lower angiogenesis, vascular function and capillary density [4]. This suggests that lower fat density may be a marker of tissue-level dysfunction, indicating higher lipid content and hypertrophy, as well as decreased perfusion. We found VAT and SAT density negatively correlated with fat areas, concordant with prior research showing increased lipid and adipocyte size during fat expansion [1,5], and decreased angiogenesis in morbid obesity [4]. Overall, increased fat CT density after RYGB likely reflects contraction of adipocyte volume as opposed to change in cell numbers.

A prior population-based study underscored the importance of density measures in abdominal fat and their relationships to cardiometabolic risk [1]. Denser fat by CT is associated with higher adiponectin and lower leptin [5], suggesting an improved metabolic state. Several studies have reported that RYGB surgery leads to increased adiponectin concurrent with decreased leptin and reductions in adipose inflammatory markers such as CRP, IL-6, and TNF- α soluble receptor-1 [6]. Although we did not obtain circulating adipocytokines, we found a 59% decrease in CRP at 12 months that correlated with increased VAT density after RYGB, independent of VAT loss or BMI decrease. Prior evidence points towards a link between visceral fat mass and systemic inflammation, suggesting VAT is an important site for IL-6 secretion and may regulate hepatic production of acute-phase reactants [7]. Our results support the hypothesis that density changes in VAT by CT may partly influence improvement of systemic inflammation.

Similar to a prior report [8], we documented improvements in lipid profile 12 months after RYGB. Prior evidence suggests decreased absorption of lipids after RYGB, which may reflect changes in the liver-gut axis regulating dietary cholesterol absorption [8]. In addition, we found that increased SAT density was a strong predictor of increased HDL-cholesterol independent of SAT loss, BMI decrease, or statin use at 12 months. Postoperative increase in HDL-cholesterol has been suggested as a promoter and strong predictor of improved microvascular function in subjects with metabolic syndrome undergoing bariatric surgery [9]. Therefore, increased SAT density after RYGB may reflect improved capillary recruitment because of improved HDL-cholesterol. Interestingly, we observed that 12-month increase in SAT density was associated with higher total fat loss. It has been previously reported that morbidly obese adults with lowest fat mass loss after bariatric surgery have greatest persistence of local fibrosis within SAT despite improvement of adipocyte hypertrophy and inflammatory infiltration [10]. Whether SAT density also reflects structural

changes that influence the degree of SAT loss after RYGB will require more detailed pathologic investigation.

In conclusion, CT density of abdominal fat increases after bariatric surgery and correlates with improved metabolic indices potentially serving as a noninvasive marker of change in adipose tissue characteristics.

Acknowledgments

Funding: National Institutes of Health, Grant Numbers: HD51959, DK093713, UL1 RR025758

References

1. Rosenquist KJ, Pedley A, Massaro JM, Theriksen KE, Murabito JM, Hoffmann U, et al. Visceral and subcutaneous fat quality and cardiometabolic risk. *JACC Cardiovasc Imaging*. 2013; 6:762–71. [PubMed: 23664720]
2. Hu HH, Chung SA, Nayak KS, Jackson HA, Gilsanz V. Differential computed tomographic attenuation of metabolically active and inactive adipose tissues: preliminary findings. *J Comput Assist Tomogr*. 2011; 35:65–71. [PubMed: 21245691]
3. Yu EW, Bouxsein M, Roy AE, Baldwin C, Cange A, Neer RM, et al. Bone loss after bariatric surgery: Discordant results between DXA and QCT bone density. *J Bone Miner Res*. 2013;1–28.
4. Farb MG, Ganley-Leal L, Mott M, Liang Y, Ercan B, Widlansky ME, et al. Arteriolar Function in Visceral Adipose Tissue Is Impaired in Human Obesity. *Arterioscler Thromb Vasc Biol*. 2012;467–73. [PubMed: 22095978]
5. Murphy RA, Register TC, Shively CA, Carr JJ, Ge Y, Heilbrun ME, et al. Adipose tissue density, a novel biomarker predicting mortality risk in older adults. *J Gerontol A Biol Sci Med Sci*. 2014; 69:109–17. [PubMed: 23707956]
6. Iannelli A, Anty R, Schneck AS, Tran A, Hébuterne X, Gugenheim J. Evolution of low-grade systemic inflammation, insulin resistance, anthropometrics, resting energy expenditure and metabolic syndrome after bariatric surgery: a comparative study between gastric bypass and sleeve gastrectomy. *J Visc Surg*. 2013; 150:269–75. [PubMed: 24016714]
7. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. *Diabetes*. 2007; 56:1010–3. [PubMed: 17287468]
8. Vix M, Diana M, Liu K-H, D’Urso A, Mutter D, Wu H-S, et al. Evolution of glycolipid profile after sleeve gastrectomy vs. Roux-en-Y gastric bypass: results of a prospective randomized clinical trial. *Obes Surg*. 2013; 23:613–21. [PubMed: 23207829]
9. Martín-Rodríguez JF, Cervera-Barajas A, Madrazo-Atutxa A, García-Luna PP, Pereira JL, Castro-Luque J, et al. Effect of bariatric surgery on microvascular dysfunction associated to metabolic syndrome: a 12-month prospective study. *Int J Obes (Lond)*. 2014;10.1038/ijo.2014.15
10. Divoux A, Tordjman J, Lacasa D, Veyrie N, Hugol D, Aissat A, et al. Fibrosis in human adipose tissue: composition, distribution, and link with lipid metabolism and fat mass loss. *Diabetes*. 2010; 59:2817–25. [PubMed: 20713683]

Figure 1.

Change in abdominal adipose tissue density and area in obese subjects 12 months after Roux-en-Y bariatric surgery (●, solid line) compared to nonsurgical obese controls (●, dotted line). * Between-group, $P = 0.001$. # Within-group, $P < 0.0001$. Error bars are $\pm$ SEM.

TABLE 1

Baseline values and change at 12 months in body composition and cardiovascular risk markers in surgical and nonsurgical subjects.

	Surgical (n=21)			Nonsurgical (n=16)		
	Baseline	Change from baseline	P-value within group	Baseline	Change from baseline	P-value within group
Age (yr)	45 ± 14	-	-	47 ± 16	-	-
Gender (F:M)	19:2			14:2		
Weight (kg)	116 ± 13	-35 ± 14	<.0001	117 ± 15	-3 ± 9	0.3
BMI (kg/m ²)	43 ± 6	-13 ± 5	<.0001	43 ± 4	-0.5 ± 2.4	0.6
Abdominal circumference (cm)	123 ± 6	-24 ± 11	<.0001	123 ± 8	-2 ± 5	0.2
VAT density (HU)	-103 ± 6	10 ± 8	<.0001	-102 ± 4	1 ± 4	0.6
SAT density (HU)	-110 ± 6	14 ± 8	<.0001	-108 ± 4	1 ± 5	0.1
VAT area (cm ²)	204 ± 71	-108 ± 56	<.0001	210 ± 87	-2 ± 22	0.3
SAT area (cm ²)	487 ± 118	-216 ± 120	<.0001	497 ± 103	-23 ± 42	0.2
TAT area (cm ²)	696 ± 116	-326 ± 159	<.0001	707 ± 107	-24 ± 56	0.1
CRP (mg/L)	7.6 ± 8.0	-4.8 ± 6.6	0.0003	8.3 ± 6.6	-1.8 ± 6	0.4
Fasting plasma glucose (mg/dl)	104 ± 24	-8 ± 26	0.1	90 ± 8	5 ± 9	0.1
Total cholesterol (mg/dl)	178 ± 28	-10 ± 35	0.2	199 ± 42	-6 ± 21	0.1
HDL-cholesterol (mg/dl)	42 ± 10	16 ± 15	<.0001	54 ± 13	3 ± 8	0.2
LDL-cholesterol (mg/dl)	108 ± 25	-18 ± 29	0.02	116 ± 33	-9 ± 17	0.2
Triglycerides (mg/dl)	154 ± 109	-54 ± 67	0.0006	141 ± 72	-4 ± 37	0.9

Values are mean ± standard deviation.